Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 2
2017 1
2018 1
2019 1
2022 1
2023 2
2024 6
2025 8
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kopjar n[Author] (131 results)?
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.
Faramand RG, Zhang A, Roloff GW, Aldoss I, Advani AS, Battiwalla M, Boccucci J, Byrd K, Cassaday RD, Connor M, Dykes KC, Hilal T, Kopmar NE, Kota VK, Lee CJ, Leonard JT, Lill GR, Lin C, Logan AC, Majhail NS, Malik SA, McCauley R, Moore J, Mountjoy L, O'Connor T, O'Dwyer KM, Bobillo SO, Oliai CH, Othman T, Ramakrishnan A, Sandhu K, Schwartz M, Shaughnessy P, Srinagesh HK, Sutherland KC, Tan V, Tsai SB, Ulrickson M, Wang ES, Yaghmour G, Frey NV, Shah BD, Muffly LS. Faramand RG, et al. Among authors: kopmar ne. Transplant Cell Ther. 2026 Jun 27:S2666-6367(26)00516-6. doi: 10.1016/j.jtct.2026.06.039. Online ahead of print. Transplant Cell Ther. 2026. PMID: 42364734
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.
Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik SA, Mathews J, Shaughnessy PJ, Mountjoy L, Dykes KC, Logan AC, Schwartz MS, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg RT, Tracy SI, Yalniz FF, Yaghmour G, Pullarkat VA, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I. Othman T, et al. Among authors: kopmar ne. Blood Adv. 2026 Jun 25:bloodadvances.2026020707. doi: 10.1182/bloodadvances.2026020707. Online ahead of print. Blood Adv. 2026. PMID: 42349018
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.
Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS. Srinagesh HK, et al. Among authors: kopmar ne. Blood. 2026 Apr 23;147(17):2011-2017. doi: 10.1182/blood.2025031734. Blood. 2026. PMID: 41643192
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH. Valtis YK, et al. Among authors: kopmar n. Blood Adv. 2026 Jan 13;10(1):276-288. doi: 10.1182/bloodadvances.2025017526. Blood Adv. 2026. PMID: 41052404 Free PMC article. Clinical Trial.
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B. O'Connor TE, et al. Among authors: kopmar ne. Bone Marrow Transplant. 2025 Nov;60(11):1465-1471. doi: 10.1038/s41409-025-02693-0. Epub 2025 Aug 23. Bone Marrow Transplant. 2025. PMID: 40849364 Free PMC article.
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy.
Ng SK, Flaherty PW, Ancheta M, Tindbaek KA, Sekhon MK, Huang JJ, Portuguese AJ, Albittar A, Kopmar NE, Cowan AJ, Shadman M, Hirayama AV, Till BG, Cassaday RD, Turtle CJ, Liu C, Xie H, Leisenring WM, Gauthier J, Liang EC, Hill JA. Ng SK, et al. Among authors: kopmar ne. Transplant Cell Ther. 2025 Oct;31(10):838.e1-838.e16. doi: 10.1016/j.jtct.2025.07.022. Epub 2025 Jul 31. Transplant Cell Ther. 2025. PMID: 40752589
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Muhsen IN, Roloff GW, Faramand R, Othman T, Valtis Y, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail N, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai CH, Shaughnessy P, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz M, Sasine JP, Kumaran M, Frey N, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Muhsen IN, et al. Among authors: kopmar ne. Blood Adv. 2025 Aug 26;9(16):4081-4089. doi: 10.1182/bloodadvances.2024015779. Blood Adv. 2025. PMID: 40334068 Free PMC article.
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.
Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff JE, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras N, Baumeister SHC, Cooper SL, Hermiston M, Satwani P, Qayed M, Raikar SS, MacMillan M, Hall E, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy P, Schwartz MS, Ladha A, Yaghmour G, Kumaran MV, Bachanova V, Tracy S, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Shah BD, Muffly L, Faramand R. Lust H, et al. Among authors: kopmar ne. Blood Adv. 2025 Jun 10;9(11):2763-2772. doi: 10.1182/bloodadvances.2024014846. Blood Adv. 2025. PMID: 40127395 Free PMC article.
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.
Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu QV, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ. Gauthier J, et al. Among authors: kopmar ne. Blood Adv. 2025 Apr 22;9(8):1861-1872. doi: 10.1182/bloodadvances.2024015314. Blood Adv. 2025. PMID: 39820359 Free PMC article. Clinical Trial.
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: kopmar ne. Blood Adv. 2025 Feb 11;9(3):606-616. doi: 10.1182/bloodadvances.2024014455. Blood Adv. 2025. PMID: 39626349 Free PMC article.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Roloff GW, et al. Among authors: kopmar ne. J Clin Oncol. 2025 Feb 10;43(5):558-566. doi: 10.1200/JCO.24.00321. Epub 2024 Oct 17. J Clin Oncol. 2025. PMID: 39418622 Free PMC article.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Aldoss I, et al. Among authors: kopmar ne. Blood Adv. 2024 Dec 10;8(23):6139-6147. doi: 10.1182/bloodadvances.2024013747. Blood Adv. 2024. PMID: 39093952 Free PMC article.
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.
Kopmar NE, Othus M, Quach K, Rasmussen A, Schonhoff K, Becker PS, Walter RB, Halpern AB, Salit R, Cassaday RD, Shustov A, Stewart FM, Oehler VG, Scott BL, Sandmaier BM, Lee SJ, Estey EH, Percival MM. Kopmar NE, et al. Transplant Cell Ther. 2024 Jul;30(7):727.e1-727.e8. doi: 10.1016/j.jtct.2024.05.002. Epub 2024 May 5. Transplant Cell Ther. 2024. PMID: 38710302 Free PMC article.
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Kopmar NE, Gooley T, Curley N, Russell K, Shaw C, Schonhoff K, Lim J, Halpern AB, Walter RB, Scott BL, Appelbaum J, Hendrie PC, Estey EH, Percival MM. Kopmar NE, et al. Leuk Lymphoma. 2023 May;64(5):1057-1059. doi: 10.1080/10428194.2023.2185087. Epub 2023 Mar 9. Leuk Lymphoma. 2023. PMID: 36896478 Free PMC article. Clinical Trial. No abstract available.
Common variable immunodeficiency as the initial presentation of dyskeratosis congenita.
Allenspach EJ, Bellodi C, Jeong D, Kopmar N, Nakamura T, Ochs HD, Ruggero D, Skoda-Smith S, Shimamura A, Torgerson TR. Allenspach EJ, et al. Among authors: kopmar n. J Allergy Clin Immunol. 2013 Jul;132(1):223-6. doi: 10.1016/j.jaci.2012.11.052. Epub 2013 Feb 10. J Allergy Clin Immunol. 2013. PMID: 23403051 Free PMC article.